» Articles » PMID: 17914718

N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations

Abstract

N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug-drug interactions this procedure is still controversial. This study was to retrospectively evaluate the N-in-1 dosing approach in drug discovery with an emphasis on the potential for drug-drug interactions. The systemic clearance, volume of distribution, oral bioavailability, and renal excretion of the 31 lead compounds in rats, dogs or chimpanzees were significantly correlated between the N-in-1 dosing and discrete studies with r values of 0.69, 0.91, 0.53, and 0.83 (p < 0.005 for all), respectively. PK parameters for 11 quality control compounds which were involved in 194 N-in-1 studies for screening approximately 1000 compounds had coefficient of variations of less than 70%. The intrinsic microsomal clearances generated from the N-in-1 and discrete incubations were nearly identical (r = 0.97, p < 0.0001). The intrinsic clearances of quality control compound from the N-in-1 incubations were consistent with its discrete CL(int) estimate (cv: 5.4%). Therefore, N-in-1 dosing is a useful approach in drug discovery to quickly obtain initial PK estimates. Potential drug-drug interactions that result in confounding PK estimates do not occur as frequently as expected.

Citing Articles

Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form.

Wallimann R, Mehta A, Mapanao A, Koster U, Kneuer R, Schindler P Eur J Nucl Med Mol Imaging. 2024; 52(4):1370-1382.

PMID: 39680064 PMC: 11839852. DOI: 10.1007/s00259-024-07018-9.


From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis.

Knabb R, Wexler R J Thromb Thrombolysis. 2021; 52(2):403-407.

PMID: 34351559 DOI: 10.1007/s11239-021-02529-w.


A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.

Bousquet-Melou A, Lespine A, Sutra J, Bargues I, Toutain P Front Pharmacol. 2021; 12:666348.

PMID: 34093195 PMC: 8173197. DOI: 10.3389/fphar.2021.666348.


Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing.

Li H, Ortiz R, Tran L, Salimi-Moosavi H, Malella J, James C AAPS J. 2012; 15(2):337-46.

PMID: 23233266 PMC: 3675729. DOI: 10.1208/s12248-012-9435-5.


Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.

Lv H, Zhang X, Sharma J, Reddy M, Reddy E, Gallo J AAPS J. 2012; 15(1):250-7.

PMID: 23180160 PMC: 3535101. DOI: 10.1208/s12248-012-9428-4.